Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer.

Johnson SD, De Costa AM, Young MR.

Cancers (Basel). 2014 Apr 2;6(2):756-70. doi: 10.3390/cancers6020756.

2.
3.

Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Johnson SD, Levingston C, Young MR.

Anticancer Res. 2016 Jul;36(7):3261-70.

5.

Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.

Young MR, Levingston CA, Johnson SD.

Int J Cancer. 2016 May 15;138(10):2487-98. doi: 10.1002/ijc.29989.

PMID:
26756968
6.
8.

Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.

De Costa AM, Schuyler CA, Walker DD, Young MR.

Cancer Immunol Immunother. 2012 Jun;61(6):927-39. doi: 10.1007/s00262-011-1154-8.

PMID:
22116344
9.

Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma.

Young MR, Neville BW, Chi AC, Lathers DM, Boyd Gillespie M, Day TA.

Cancer Immunol Immunother. 2007 Jul;56(7):1077-86.

PMID:
17096152
10.

Premalignant lesions skew spleen cell responses to immune modulation by adipocytes.

Vielma SA, Klein RL, Levingston CA, Young MR.

Anticancer Res. 2013 May;33(5):1809-18.

PMID:
23645725
11.
12.

Phospholipid metabolite expression by head and neck squamous cell carcinoma.

Mann EA, Spiro JD, Chen LL, Kreutzer DL.

Arch Otolaryngol Head Neck Surg. 1994 Jul;120(7):763-9.

PMID:
8018329
13.

Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.

Levingston CA, Young MR.

Int J Cancer. 2017 Apr 1;140(7):1609-1619. doi: 10.1002/ijc.30543.

14.

Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck.

Lathers DM, Achille NJ, Young MR.

Hum Immunol. 2003 Dec;64(12):1160-6.

PMID:
14630398
15.

Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development.

Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B.

Br J Cancer. 2010 Oct 12;103(8):1245-54. doi: 10.1038/sj.bjc.6605891.

16.

Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck.

Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C.

Int J Cancer. 2003 Aug 10;106(1):34-44.

17.

Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.

Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, Smith CW, Enamorado I, Yeh NT, Kroog GS, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher LL, Van Waes C.

Clin Cancer Res. 1999 Jun;5(6):1369-79.

18.

Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.

Nakano H, Kishida T, Asada H, Shin-Ya M, Shinomiya T, Imanishi J, Shimada T, Nakai S, Takeuchi M, Hisa Y, Mazda O.

J Gene Med. 2006 Jan;8(1):90-9.

PMID:
16097036
20.

Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Gildener-Leapman N, Ferris RL, Bauman JE.

Oral Oncol. 2013 Dec;49(12):1089-96. doi: 10.1016/j.oraloncology.2013.09.009. Review.

Supplemental Content

Support Center